BridgeBio Pharma, Inc.
BBIO
$66.79
$0.841.27%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 579.96M | 502.08M | 353.78M | 235.81M | 127.42M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 579.96M | 502.08M | 353.78M | 235.81M | 127.42M |
| Cost of Revenue | 28.26M | 20.96M | 14.94M | 8.97M | 5.92M |
| Gross Profit | 551.70M | 481.11M | 338.84M | 226.84M | 121.50M |
| SG&A Expenses | 588.76M | 531.23M | 467.92M | 399.12M | 329.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.08B | 1.00B | 948.75M | 881.55M | 812.33M |
| Operating Income | -504.22M | -502.06M | -594.97M | -645.74M | -684.91M |
| Income Before Tax | -729.45M | -732.50M | -803.98M | -781.76M | -675.64M |
| Income Tax Expenses | 435.00K | 435.00K | 1.71M | 3.25M | 1.15M |
| Earnings from Continuing Operations | -729.89 | -732.94 | -805.69 | -785.01 | -676.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 8.33M | 8.01M | 8.57M | 8.59M | 8.83M |
| Net Income | -721.55M | -724.93M | -797.12M | -776.42M | -667.97M |
| EBIT | -504.22M | -502.06M | -594.97M | -645.74M | -684.91M |
| EBITDA | -498.88M | -496.63M | -589.60M | -640.23M | -679.15M |
| EPS Basic | -3.75 | -3.78 | -4.19 | -4.09 | -3.53 |
| Normalized Basic EPS | -2.26 | -2.21 | -2.48 | -2.60 | -2.67 |
| EPS Diluted | -3.75 | -3.78 | -4.19 | -4.09 | -3.53 |
| Normalized Diluted EPS | -2.26 | -2.21 | -2.48 | -2.60 | -2.67 |
| Average Basic Shares Outstanding | 770.71M | 766.07M | 761.95M | 758.61M | 755.68M |
| Average Diluted Shares Outstanding | 770.71M | 766.07M | 761.95M | 758.61M | 755.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |